The Global Health Body Issues Warning Over Acute Lack of Obesity Medications
Fewer than 10% of individuals who could benefit from obesity jabs including Wegovy can access them, states the global health agency as it releases its first advice on the drugs.
Given more than one billion individuals worldwide currently classified as obese, it is urging broader and more equitable access to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The latest guidelines affirms that excess weight is a long-term condition that can be addressed with comprehensive and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key hurdles to widespread availability to the treatments that can assist patients in reducing substantial weight, explains the agency.
Skinny Jab Shortage
Despite the present most optimistic scenario, the supply of these medications would only suffice for about 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The advice encourages governments and firms to increase access, through strategies like voluntary licensing.
Exclusive production rights on a key compound – the primary component of the drug Wegovy – is due to expire in multiple countries in 2026.
How Weight-Loss Drugs Work
The injections imitate a body's own hormone to delay gastric emptying, suppress the appetite and increase feelings of fullness so individuals consume fewer calories.
Patients typically start to lose weight in the initial weeks of beginning the weekly injections.
Studies points to patients may put most of the weight back on a year later of stopping the treatment, when their typical food cravings return.
To be overweight or obese elevates your chance for contracting health problems, such as type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight concerns people in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
